CVS Group Plc (LON:CVSG) maintained its full-year guidance for fiscal 2026 despite UK market challenges, reporting 5.8% revenue growth to £356.9 million for the first half. The veterinary services provider met market expectations with sales aligning closely to consensus estimates of £357 million, according to results released Thursday.

The company's like-for-like sales growth improved to approximately 2.7%, recovering from negative 1.1% growth in the first half of 2025. UK revenues totaled £320.6 million while Australian operations contributed £36.3 million. Adjusted EBITDA increased 3.9% to £67.7 million, falling short of consensus expectations of £69.6 million due to inflationary pressures from wage increases and higher national insurance costs.

UK operations showed mixed performance with lower customer footfall partially offset by demand in referral services, while Australian operations continued delivering stronger results. The company's net debt excluding leases rose to £158.3 million, increasing leverage to 1.41 times net debt to EBITDA. CVS Group expressed confidence in delivering fiscal 2026 results in line with market expectations, with consensus adjusted EBITDA estimates at £141.9 million, and highlighted progress in Australia while acknowledging ongoing UK headwinds.